NASDAQ:CHRS
Coherus Oncology, Inc.
Coherus Oncology, Inc.'s revenue grew 59.8% in fiscal 2025 to $42.2M while operating margin rose to −429.5%. The diluted share count rose 2.3%.Summary generated from Coherus Oncology, Inc.'s SEC filings. Latest annual report filed Mar 9, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$42.2M
Revenue growth+59.8%
Revenue, 5-yr CAGR−38.4%
Gross margin67.2%
Operating margin−429.5%
Net margin398.4%
ROICn/a
Return on equityn/a
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+2.3%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 327 | 211 | 257 | 26 | 42 |
| Operating income | −264 | −257 | −203 | −200 | −181 |
| Net income | −287 | −292 | −238 | 29 | 168 |
| Free cash flow | −39 | −243 | −175 | n/a | n/a |
Recent filings
- 8-KOther events
Aug 28, 2026 - 8-KRegulation FD disclosure
Aug 17, 2026 - 8-KEntry into a material agreement
Aug 17, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 5, 2026 - 8-KResults of operations and financial condition
Aug 5, 2026 - 8-KChange in auditor
Jun 15, 2026 - 4Insider transaction report
Jun 9, 2026 - 4Insider transaction report
Jun 9, 2026